First line anti-inflammatory treatment for asthma: inhaled steroid or leukotriene antagonist? Source: Eur Respir J 2002; 20: Suppl. 38, 93s Year: 2002
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001
TNFα-induced glucocorticoid resistance: Effect of steroidal and non-steroidal GR agonists, formoterol and inhibition of inflammatory signalling Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids Source: Eur Respir J, 50 (2) 1700670; 10.1183/13993003.00670-2017 Year: 2017
Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010
Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review Source: Annual Congress 2011 - Asthma management and response Year: 2011
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids Source: Eur Respir J 2006; 27: 511-516 Year: 2006
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
The effects of formyl peptide receptor agonist on the asthma pathogenesis Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010
Leukotriene receptor antagonist (LTRA) montelukast for the treatment of acute bronchiolitis in infants Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Anti-inflammatory efficacy of formoterol via transrepressive mechanisms is independent of the glucocorticoid receptor in human bronchial epithelial cells Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017